A Comparison of Efficacy of Two Brands of Enoxaparin in COVID-19 Patients: A Pilot Study
Dhvani Dave
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT Campus, Changa-388421, India.
Jalpa Suthar *
Department of Pharmacology and Clinical Pharmacy, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT Campus, Changa-388421, India.
Jhanvi Patel
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT Campus, Changa-388421, India.
*Author to whom correspondence should be addressed.
Abstract
Introduction: Enoxaparin is a complex and biologically derived low-molecular-weight Heparin which is approved for a variety of clinical indications associated with thromboembolic events such as Deep Vein Thrombosis and Venous Thromboembolism. During COVID-19 it was frequently used as prophylaxis in the treatment of thromboembolic events. Nowadays, many brands have come up in the market for the same.
Objective: In Tricolour Hospital located in Vadodara, Gujarat, the ongoing brand of Enoxaparin 0.6 i.e., Clexane (Sanofi) falls short as well as in the pharmaceutical market. Hence, the management decided to procure another brand of Enoxaparin until Clexane is available to the vendors. Therefore, the present study was planned to study efficacy of two brands of Enoxaparin –one is Coguparine, (Venus Pharmaceuticals) and another LMWX- (Abbott) in COVID-19 patients in an isolation ward of hospital. The aim of present study was to compare the efficacy of two brands of Enoxaparin (Coguparine vs LMWX) for prophylactic treatment of thromboembolism observed in COVID-19 patients.
Methodology: Patients were randomly divided into 2 groups- A and B. Patients in group A received Coguparine while patients in group B received LMWX. Statistical analysis was carried out using paired t-test.
Results: The laboratory reports of patients in Group-A presented few abnormal improvements in the Complete blood count but there was no concrete evidence about the same. On the other hand, patients in Group-B receiving LMWX showed improvement in CBC profile. Also, there was significant difference observed in C-Reactive Protein and D-Dimer profiles in both the brands.
Conclusion: This showed that for the cost-effective treatment and procurement of Enoxaparin there is no harm in using generic formulation of Enoxaparin as and when required. But LMWX was proved to be of standard quality in terms of efficacy.
Keywords: Enoxaparin, LMWX, coguparine, COVID-19, complete blood count, efficacy